Bedrijfsoverzicht
Lyell Immunopharma, Inc. is a clinical-stage cell therapy enterprise dedicated to the development of chimeric antigen receptor (CAR) T-cell product candidates designed for patients suffering from hematologic malignancies and solid tumors. The company operates within the healthcare sector, specifically in the biotechnology industry, a domain characterized by high-risk research and development aimed at creating novel therapeutic solutions for complex medical conditions. As of the latest available data, the company holds a market capitalization of $522.32M, while its annual revenue for the trailing twelve months stands at $36,000, and the total employee count is listed as N/A. The substantial disparity between the company's significant market valuation of $522.32M and its minimal revenue of $36,000 indicates that the market is pricing in the future potential of its pipeline assets rather than current cash-generating operations, a common characteristic for early-stage biotechnology firms where value is derived from intellectual property and clinical trial progress rather than immediate sales.
Financiële gezondheid
The financial statements reveal a net income of $-274,448,000 and an EBITDA of $-186,746,000 against a revenue figure of $36,000, highlighting a cost structure dominated by significant operating expenses typical of clinical-stage development. This massive gap between the negligible revenue of $36,000 and the substantial net loss of $274.44 million underscores that the company is burning through capital to advance its product candidates through clinical trials rather than generating profit from sales. The free cash flow is reported at $-81,467,128, which signifies a negative cash position where the company is spending more on capital expenditures and working capital than it generates from its operations, indicating a need for external financing to sustain operations. Margin analysis shows a gross margin of 100.0%, reflecting the nature of selling intangible assets or early-stage product candidates without cost of goods sold, while the operating margin of -1024633.3% and profit margin of 0.0% illustrate the severe operational losses incurred during the research and development phase. The balance sheet presents $247.22M in cash against $50.99M in debt, resulting in a debt-to-equity ratio of 20.55, which suggests a leveraged position relative to equity but provides a substantial liquidity buffer given the cash reserves. The current ratio stands at 5.28, indicating a strong ability to cover short-term liabilities with short-term assets, providing a degree of financial stability despite the heavy reliance on cash reserves to fund ongoing operations. Return on equity is -87.0% and return on assets is -29.8%, metrics that reveal management is currently utilizing the company's capital base to generate losses rather than positive returns, a standard metric for pre-revenue biotechnology companies where reinvestment exceeds yield.
Waarderingsbeoordeling
The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -26.65, the latter implying that the market expects earnings to remain negative or for the company to require continued capital infusion before becoming profitable. The price-to-book ratio is 1.92, suggesting that the stock trades at a premium of nearly double its book value, which often reflects investor confidence in the future commercial potential of the underlying clinical assets. Alternative valuation measures such as the price-to-sales ratio of 14508.96 and an EV/EBITDA of -1.74 further emphasize that traditional earnings-based valuation models are not applicable, pointing instead to a valuation driven by pipeline value and future revenue potential rather than current profitability. The stock has experienced significant volatility, trading between a 52-week low of $7.65 and a 52-week high of $45.00. Without a specific current price provided in the facts to calculate the exact percentage deviation, the range itself highlights the speculative nature of the asset, which can fluctuate widely based on clinical trial data and regulatory news. The beta value is -0.07, a unique and anomalous figure that technically indicates an inverse correlation to market movements or a measurement artifact, as biotechnology stocks typically exhibit positive beta values reflecting their correlation with broader market risk.
Growth & Income
The company reports a revenue growth year-over-year of -45.5%, while earnings growth is N/A due to the absence of prior comparable earnings in a traditional sense. The negative revenue growth indicates a contraction in current sales, which is typical for a company where revenue is currently negligible compared to the high fixed costs of development. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all generated cash to fund its clinical trials and operational expenses rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and zero dividend distribution, reflecting a strategic focus on capitalizing research and development to bring potential therapies to market before achieving commercial scale.